DIVISLAB's weekly performance was modest, with a 0.56% return, outperforming peers DRREDDY and SUNPHARMA, but underperforming CIPLA. The stock's volatility was relatively high at 37.69%, indicating a riskier investment. Despite this, the Sharpe Ratio of 0.07 suggests that the return was not entirely justified by the level of risk taken. Overall, DIVISLAB's performance was decent, but investors should be cautious of its high volatility.

[Volatility: 37.69%]